1 Unité de physiologie, physiopathologie de la digestion et du métabolisme des proténes, Station de Recherches Porcines, Institut National de la Recherche Agronomique, 35590 Saint-Gilles; and 2 Unité Institut National de la Santé et de la Recherche Médicale U 45, 69437 Lyon, France
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The aim of this study was to evaluate the nervous and humoral pathways involved in short-chain fatty acid (SCFA)-induced ileal brake in conscious pigs. The role of extrinsic ileal innervation was evaluated after SCFA infusion in innervated and denervated Babkin's ileal loops, and gastric motility was measured with strain gauges. Peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) concentrations were evaluated in both situations. The possible involvement of absorbed SCFA was tested by using intravenous infusion of acetate. Ileal SCFA infusion in the intact terminal ileum decreased the amplitude of distal and terminal antral contractions (33 ± 1.2 vs. 49 ± 1.2% of the maximal amplitude recorded before infusion) and increased their frequency (1.5 ± 0.11 vs. 1.3 ± 0.10/min). Similar effects were observed during SCFA infusion in ileal innervated and denervated loops (amplitude, 35 ± 1.0 and 34 ± 0.8 vs. 47 ± 1.3 and 43 ± 1.2%; frequency, 1.4 ± 0.07 and 1.6 ± 0.06 vs. 1.1 ± 0.14 and 1.0 ± 0.12/min). Intravenous acetate did not modify the amplitude and frequency of antral contractions. PYY but not GLP-1 concentrations were increased during SCFA infusion in innervated and denervated loops. In conclusion, ileal SCFA inhibit distal gastric motility by a humoral pathway involving the release of an inhibiting factor, which is likely PYY.
Babkin loops; peptide YY; glucagon-like peptide-1.
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
NUTRIENTS IN THE ILEUM INHIBIT gastric motility and emptying, a phenomenon called the "ileal brake" (25, 28). Gastroparesia was also triggered by short-chain fatty acids (SCFA) infused in the distal ileum in pigs (7, 9). Unlike nonabsorbed nutrients originating from the upper part of the gut, SCFA were spontaneously present in the distal ileum as a result of frequent coloileal reflux episodes (8). These events, more frequent after a meal, supply SCFA concentration large enough to initiate an ileal brake.
The mechanisms of the ileal brake are still controversial (21). The role of a nervous pathway between the ileum and the stomach has been identified in gastric emptying (26) and proximal gastric tone (2) for carbohydrates. However, in these models, ileal or jejunal infusion will eventually reach the colon, for which clear evidence of a nervous pathway inhibiting gastric motility has been established (4, 6, 12, 31). This, together with data obtained in humans and in dogs indicating that peptide YY (PYY) and possibly glucagon-like peptide-1 (GLP-1) increase during ileal infusion of nutrients, suggests that the ileal brake might be primarily of a humoral nature.
The aim of this study was to evaluate the roles of nervous and humoral pathways between the ileum and the stomach that are activated by the presence of SCFA in the distal ileum as a result of spontaneously occurring coloileal reflux. This was achieved by monitoring gastric motor activity during SCFA infusion in innervated and denervated ileal Babkin loops. The amount of SCFA infused was identical to that present during postprandial reflux episodes. Since SCFA infused in the loops might be absorbed and act directly on gastric motility, we also tested the effect of intravenous infusion of SCFA. Finally, the concentrations of the candidate peptides for a humoral modulation of nutrients inducing ileal brake (PYY and GLP-1) were measured in the same experimental conditions.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Experimental design. Fifteen female Large White pigs (41 ± 1.0 kg, 3 mo old) were divided into three groups of equal size. Group I, with an intact small bowel, received intravenous or ileal infusions of SCFA. Innervated ileal Babkin loops (3) were constructed in group II to prevent SCFA passage into the cecocolonic segment. Denervation of a similarly created loop was performed in group III. Four animals taken at random in groups II (2 animals) and III (2 animals) were also used, in the interval between motility experiments, for blood sampling and subsequent PYY and GLP-1 assays.
Surgical preparation. Under aseptic conditions and general anesthesia, a midline abdominal laparotomy was performed in the three groups. The anesthesia protocol has previously been described in detail (8). Briefly, preanesthesia was induced by ketamine (5 mg/kg im). Administration of halothane (5% vol/vol) by a face mask suppressed pharyngotracheal reflex, allowing intubation. Anesthesia was maintained with inhaled halothane (3% vol/vol). Three strain gauge force transducers (Vishay Measurements) were sutured 8 (proximal antrum), 5 (distal antrum), and 3 (terminal antrum) cm proximal to the pylorus. Wires were brought subcutaneously to exit between the shoulders. A silicon catheter (ID = 0.76 mm) was introduced into the external jugular vein and brought subcutaneously between the shoulders.
The surgical preparation at the ileal level differed among groups. In group I, with the use of a right lateral laparotomy, a silicon catheter (ID = 1.5 mm) used for ileal SCFA infusions was inserted in the distal ileum 15 cm proximal to the ileocecal sphincter. In groups II and III, ileal Babkin loops (3) were created. The last 20 cm of the ileum were isolated from the terminal ileum and placed under the skin. The two ends of the loop were passed through the skin to create two stomies. Bowel continuity was restored by an end-to-end anastomosis. A fine silicon sheet was wrapped loose around the loop's mesenteric arcade to help locate the arcade during the following surgical procedure, which was performed in group III only. For group III, 1 mo later and once revascularization of the loop was completed, the mesenteric arcade of the loop was cut to suppress extrinsic innervation. Animals were allowed 1 wk to recover from surgery before the start of the recordings. Once a day and when experiments were not performed, the loops were rinsed using Sustacal (1 ml/min for 1 h; Mead Johnson). At the end of the experiments, the animals were killed with an overdose of pentobarbital sodium, and tissues were sampled from the loops for histopathological evaluation. No major alteration could be observed in all loop samples, but the height of the villi and the thickness of the muscular layer were less compared with intact ileum collected in pigs of identical age and weight at the slaughterhouse.Experimental protocol. Studies were performed in conscious pigs at 2-day intervals and after at least 14 h of fasting. Pigs did not have access to water during experiments.
In groups I, II, and III, the effects of an ileal infusion of a mixture containing 60% acetate (C2), 30% propionate (C3), and 10% butyrate (C4) (pH 6.8; 0.5 M) administered at a rate of 2.4 ml/min for 1 h were evaluated compared with the infusion at the same rate and duration of saline. This mixture has the same SCFA chemical composition as the colonic refluxate in pigs. In group I only, the effect of intravenous acetic acid (pH 6.8; 1.2 M, 1 ml/min for 1 h), the only SCFA found in the blood after intestinal infusion of C2, C3, and C4 mixture (15), was tested vs. an identical intravenous infusion of saline. All infusions were started 5 min after the onset of an antral phase I of a migrating motor complex (MMC). Motility measurements were performed for 3 h before and after the infusion. Blood samples were collected twice before the start of the ileal infusion. Afterwards, blood was sampled at 0, 15, 30, 45, 60, 75, 90, 120, 150, and 180 min relative to the onset of SCFA infusion. Plasma was immediately separated (4,500 rpm, 5 min) and stored atRecordings. Strain gauge signals were recorded on a multichannel chart recorder (Gould 4042 and Beckman R611) using a half bridge coupler (1B31; Analog Devices) and simultaneously digitized (15 Hz) on a computer (Macintosh II; Apple Computer) using an A/D card (NB MI016; National Instruments) after low-pass filtration at 10 Hz. Data were stored digitally for subsequent analysis.
Peptides assay. RIA for PYY was performed as previously described with antiserum A4D obtained from a rabbit after repeated injection of synthetic porcine PYY conjugated to BSA through ethylcarbodiimide condensation (5). This antiserum, which cross-reacted <0.1% with porcine pancreatic polypeptide and NPY, was used in the assay at a final dilution of 1:800,000. The synthetic peptide was iodinated with carrier-free Na-125I by means of the chloramine-T reagent and was purified by reverse-phase HPLC as previously described (5). The minimum detectable amount of PYY and the ID50 of the assay were 1 and 7 fmol/tube, respectively. Plasma samples run on a Sephadex G-50 column revealed a single immunoreactive peak coeluting with the synthetic peptide.
The GLP-1 assay was performed as described earlier (1, 23). Briefly, antiserum against GLP-1-(7-36) amide was obtained in a rabbit by immunization with synthetic GLP-1-(7-36) amide conjugated to BSA and was used at a final dilution of 1:300,000. The reactivity of the antiserum 199D was 100% for GLP-1-(7-36) amide, 84% for GLP-1-(1-36) amide, and <0.1% for GLP-1-(1-37), GLP-1-(7-37), GLP-2, glucagon, secretin, vasoactive intestinal peptide, and gastrointestinal inhibitory peptide. The synthetic GLP-1-(7-36) amide was radioiodinated using the chloramine-T method and purified by reverse HPLC. The detection limit and ID50 were 0.6 and 4.5 fmol/tube, respectively. The plasma samples (1 ml) were treated with 2 volumes of ethanol. The ethanol extracts were dried and kept atData analysis. Strain gauge data were automatically analyzed using MAD 3.2 software to evaluate the amplitude and frequency of antral contractions (7, 9). The amplitude of contractions was expressed as the percentage of the maximal amplitude recorded before the infusion. Motility index was calculated, for the distal antral strain gauge only, as the sum of amplitude multiplied by frequency of all contractions recorded during 1 h. It was expressed as a percentage of the maximum amplitude recorded before the infusion per minute. Propagation profiles of antral contractions were expressed as the percentage of antral contractions occurring in sequence on three adjacent recording sites. The time window during which contraction had to occur to be part of a propagated pattern was ±5 s (for adjacent recording locations). Contractions that did not fulfill this criteria were considered stationary contractions.
Statistical analysis was performed using Statview software (SAS Institute). Data are expressed as means ± SE. Comparisons between SCFA and saline infusions or between acetate and saline infusions within the same experimental group were achieved by one-way analysis of variance. Comparisons between experimental groups were performed by two-way analysis of variance. Fischer protected least significant differences test was used in both situations to test the level of significance of P < 0.05. Comparisons for PYY and GLP-1 profiles were achieved with repeated-measures analysis of variance. ![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Parenteral acetate.
The amplitude and frequency of antral contractions were not
significantly modified during intravenous acetate compared with saline
infusion (Figs. 1 and
2). Distal antral motility index was also
similar for acetate and saline infusions (3,225 ± 476.4 vs.
3,899 ± 440.1%/min for saline and acetate infusions,
respectively; P > 0.05). Recurrence and duration of
the MMC phases were identical (P > 0.05) for both
treatments; hence the MMC duration was not significantly different
(69 ± 8 vs. 62 ± 4 min). Antral contraction propagation
patterns were identical for saline and acetate infusions (stationary
contractions, 17 ± 3.7 vs. 18 ± 2.3%; contractions propagated over the 3 recording sites, 46 ± 6.2 vs. 41 ± 5.2%, respectively, during saline and C2 infusions;
P > 0.05).
|
|
Enteral SCFA.
SCFA mixture infused in the intact terminal ileum (group I)
decreased the amplitude and increased the frequency of antral contractions irrespective of the recording site (Figs.
3 and 4). The motility index recorded at the distal antral level was reduced by
35% compared with saline (2,624 ± 503.4 vs. 4,077 ± 388.2%/min; P < 0.05). Gastric MMC duration was
unchanged during SCFA infusion compared with saline (74 ± 4 vs.
82 ± 4 min; P > 0.05). However, the first MMC
recorded at the completion of the infusion lasted significantly longer
for SCFA than saline (94 ± 5 vs. 67 ± 4 min; P < 0.05). Afterwards, the characteristics of the MMC
were similar to preinfusion ones. The percentage of stationary
contractions was greater during ileal SCFA infusion compared with
saline, whereas that of propagated ones was reduced (Table
1).
|
|
|
PYY concentrations.
PYY plasma concentration was increased from 15 to 60 min after the
onset of ileal saline or SCFA infusion compared with preinfusion values
(414 ± 57.0 vs. 294 ± 51.3 pg/ml). Nevertheless, this
increase was significantly greater for SCFA infusion at 30 and 45 min
compared with saline (Fig. 5). Plasma PYY
concentrations recovered values similar to basal level 15 min after the
completion of infusion. The area under the curve of PYY response to
ileal SCFA was increased compared with saline infusion (6,648 ± 2,932.6 vs. 285 ± 2,281.8 pg · ml
1 · h; P < 0.05).
The effect of SCFA infusion on PYY concentration was not significantly
different (P > 0.05) for groups II and
III.
|
GLP-1 concentrations.
Plasma GLP-1 concentration increased during SCFA and saline infusions
compared with preinfusion values. Nevertheless, no significant differences were noticed between saline and SCFA infusions irrespective of sampling time (Fig. 5). Similarly, the area under the curve was
identical for both situations (111 ± 98.7 vs. 299 ± 107.9 pg · ml1 · h, respectively, for saline
and SCFA; P > 0.05). Finally, there was no
difference between GLP-1 responses in groups II and
III (P > 0.05).
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Using innervated and denervated ileal loops, we have demonstrated that, in conscious pigs, extrinsic ileal innervation was not necessary for ileal SCFA to inhibit gastric motility. PYY but not GLP-1 was released in the bloodstream during SCFA ileal infusion and might be responsible for gastric motility inhibition.
There is considerable evidence that the distal intestine participates in the regulation of proximal gut function (19). In physiological situations, stimulation of the ileum occurs in the late postprandial regulation of gastrointestinal response (17), whereas in malabsorptive states, impaired gastric emptying and intestinal transit are adaptative answers to compensate for the absorption deficit (27). The ileal brake consists of a variety of motor, secretory, and behavioral responses, including gastric motor inhibition (10), reduction of gastric emptying rate (30), lower interdigestive gastric acid output (18), and suppression of short-term food intake (29). The chemical nature of the nutrients triggering the ileal brake is species dependent and controversial since in dogs glucose, lipids, and proteins have been found effective (27), whereas in humans proteins and glucose are not (30). Nevertheless, lipids are the most potent class of compounds. Whereas their mechanism of action toward ileal mucosa is not well understood, Lin et al. (21) suggested that they might involve the end product of lipid digestion i.e., SCFA. This, together with the presence of SCFA within the ileum as a result of coloileal reflux (8), might explain the exquisite sensitivity of the ileal brake to SCFA in pigs.
The results from parenteral acetate infusion invalidate the possibility
that absorbed SCFA per se might represent an effective humoral
inhibitory agent toward gastric motility. Indeed, 30 µmol · kg1 · min
1
intravenous acetate, the sole SCFA present in the blood after SCFA
mixture ileal infusion (15), was ineffective in triggering significant antral motility changes, whereas a similar amount infused
within the ileum inhibited gastric motility. Similarly, the antral
inhibition was not related to colonic stimulation by SCFA transported
together with the intestinal fluid from the ileum to the colon, since
gastroparesia was also present while SCFA were perfused in the ileal
loop (group II).
Our demonstration of a pure humoral pathway at the origin of an ileal brake in pigs is in accordance with the reversion of lipid-induced ileal brake with the use of PYY immunoneutralization in dogs (21). Nevertheless, the previous experiments are partially in contradiction with an extrinsic nervous pathway triggered either by carbohydrate (26) or a carbohydrate-containing mixture (2) demonstrated in dogs. Although the characteristics of the antral contractions have not been evaluated in the former studies, they clearly demonstrated that undigested nutrients effectively inhibit gastric tone and total gastric emptying rate by a nervous pathway. Hence, it could be speculated that the ileal brake triggered by fat is of humoral origin, whereas the one triggered by carbohydrate is of nervous origin.
Whereas our experiment univocally demonstrates the humoral nature of the SCFA-induced ileal brake, the inhibitory substance released by the ileum wall is still putative. GLP-1 was not involved since its plasmatic concentrations were unchanged by SCFA infusion. This confirms the secondary role of GLP-1 already suggested in humans (20). On the contrary, the increased plasmatic PYY concentration after SCFA infusion within the innervated or denervated ileal loop is indicative of a possible role for this peptide. Unlike in previous experiments in rats and rabbits (11, 22, 24), PYY was actually released by the ileum and not as a result of an SCFA-induced colonic stimulation. Surprisingly, PYY concentrations were about doubled during ileal SCFA infusion in pigs, whereas in rats, PYY concentrations were unchanged under the same circumstances (11). However, major interspecies differences in PYY responses have already been mentioned in response to intraluminal nutrient infusions (14). In addition to an overall increase in PYY concentration, supplementary events seem to support a role for PYY in SCFA-induced ileal brake. PYY concentration after SCFA was significantly different from saline 30 min after the onset of infusion, a delay consistent with the onset of gastric inhibition. Similarly, whereas gastric inhibition lasted 15 min after the completion of the SCFA infusion, PYY peak also extended for a similar duration. Finally, the concept of PYY participation in the ileal brake has been suggested by several groups (13, 16, 20) and has received major additional support from the finding that immunoneutralization of PYY reversed the inhibitory consequences of ileal infusion of lipids (21).
In conclusion, we have demonstrated that gastric inhibition triggered by SCFA infused in the ileum in quantities similar to those observed during physiological coloileal reflux episodes is of humoral nature. It likely involves PYY release from the ileal mucosa. An extrinsic neuronal pathway, if present, is not mandatory for the reflex to occur.
![]() |
FOOTNOTES |
---|
Address for reprint requests and other correspondence: C. H. Malbert, Station de Recherches Porcines, INRA, 35590 Saint-Gilles, France (E-mail: malbert{at}st-gilles.rennes.inra.fr)
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 22 November 1999; accepted in final form 31 May 2000.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Abello, J,
Ye F,
Bosshard A,
Bernard C,
Cuber JC,
and
Chayvialle JA.
Stimulation of glucagon-like peptide-1 secretion by muscarinic agonist in a murine intestinal endocrine cell line.
Endocrinology
134:
2011-2017,
1994[Abstract].
2.
Azpiroz, F,
and
Malagelada JR.
Vagally mediated gastric relaxation induced by intestinal nutrients in the dog.
Am J Physiol Gastrointest Liver Physiol
251:
G727-G735,
1986[ISI][Medline].
3.
Babkin, BP.
Secretory Mechanism of the Digestive Glands. New York: Hoeber, 1944.
4.
Basilisco, G,
Phillips SF,
Cullen JJ,
and
Chiravuri M.
Tonic responses of canine proximal colon: effects of eating, nutrients, and simulated diarrhea.
Am J Physiol Gastrointest Liver Physiol
268:
G95-G101,
1995
5.
Bosshard, A,
Chery-Croze S,
Cuber JC,
Dechelette MA,
Berger F,
and
Chayvialle JA.
Immunocytochemical study of peptidergic structures in Brunner's glands.
Gastroenterology
97:
1382-1388,
1989[ISI][Medline].
6.
Cherbut, C,
Ferrier L,
Roze C,
Anini Y,
Blottiere H,
Lecannu G,
and
Galimiche JP.
Short-chain fatty acids modify colonic motility through nerves and polypeptide YY release in the rat.
Am J Physiol Gastrointest Liver Physiol
275:
G1415-G1422,
1998
7.
Cuche, G,
and
Malbert CH.
Ileal short-chain fatty acids inhibit transpyloric flow in pigs.
Scand J Gastroenterol
34:
149-155,
1999[ISI][Medline].
8.
Cuche, G,
and
Malbert CH.
Relationships between cecoileal reflux and ileal motor patterns in conscious pigs.
Am J Physiol Gastrointest Liver Physiol
274:
G35-G41,
1998
9.
Cuche, G,
and
Malbert CH.
Short-chain fatty acids present in the ileum inhibit fasting gastrointestinal motility in conscious pigs.
Neurogastroenterol Motil
11:
219-226,
1999[ISI][Medline].
10.
Fone, D,
Horowitz M,
Read N,
Dent J,
and
Maddox A.
The effect of terminal ileal triglyceride infusion on gastroduodenal motility and the intragastric distribution of a solid meal.
Gastroenterology
98:
568-575,
1990[ISI][Medline].
11.
Fu-Cheng, X,
Anini Y,
Chariot J,
Voisin T,
Galmiche JP,
and
Rozé C.
Peptide YY release after intraduodenal, intraileal and intracoloninc administration of nutrients in rats.
Pflügers Arch
431:
66-75,
1995[ISI][Medline].
12.
Fucheng, XM,
Chariot J,
Castex N,
Galmiche JP,
and
Roze C.
Mechanisms of peptide YY release induced by an intraduodenal meal in rats: neural regulation by proximal gut.
Pflügers Arch
433:
571-579,
1997[ISI][Medline].
13.
Greeley, GH,
Hashimoto T,
Izukura M,
Gomez G,
Jeng J,
Hill FL,
Lluis F,
and
Thompson JC.
A comparison of intraduodenally and intracolonically administrated nutrients on the release of Peptide-YY in the dog.
Endocrinology
125:
1761-1765,
1989[Abstract].
14.
Hill, FLC,
Zhang T,
Gomez G,
and
Greeley GH.
Peptide YY, a new gut hormone (a mini-review).
Steroids
56:
77-82,
1991[ISI][Medline].
15.
Imoto, S,
and
Namioka S.
VFA metabolism in the pig.
J Anim Sci
47:
479-487,
1978[ISI][Medline].
16.
Jian, R,
Besterman HS,
Sarson DL,
Aymes C,
Hostein J,
Bloom SR,
and
Rambaud JC.
Colonic inhibition of gastric secretion in man.
Dig Dis Sci
26:
195-201,
1981[ISI][Medline].
17.
Keller, J,
Runzi M,
Goebell H,
and
Layer P.
Duodenal and ileal nutrient deliveries regulate human intestinal motor and pancreatic responses to a meal.
Am J Physiol Gastrointest Liver Physiol
272:
G632-G637,
1997
18.
Layer, P,
Holst JJ,
Grandt D,
and
Goebell H.
Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans.
Dig Dis Sci
40:
1074-1082,
1995[ISI][Medline].
19.
Layer, P,
Peschel S,
Schlesinger T,
and
Goebell H.
Human pancreatic secretion and intestinal motility: effects of ileal nutrient perfusion.
Am J Physiol Gastrointest Liver Physiol
258:
G196-G201,
1990
20.
Layer, P,
Schlesinger T,
Groger G,
and
Goebell H.
Modulation of human periodic interdigestive gastrointestinal motor and pancreatic function by the ileum.
Pancreas
8:
426-432,
1993[ISI][Medline].
21.
Lin, HC,
Zhao XT,
Wang LJ,
and
Wong H.
Fat-induced ileal brake in the dog depends on peptide YY.
Gastroenterology
110:
1491-1495,
1996[ISI][Medline].
22.
Longo, WE,
Ballantyne GH,
Savoca PE,
Adrian TE,
Bilchik AJ,
and
Modlin IM.
Short-chain fatty acid release of peptide YY in the isolated rabbit distal colon.
Scand J Gastroenterol
26:
442-448,
1991[ISI][Medline].
23.
Plaisancie, P,
Bernard C,
Chayvialle JA,
and
Cuber JC.
Regulation of glucagon-like peptide-1-(7-36) amide secretion by intestinal neurotransmitters and hormones in the isolated vascularly perfused rat colon.
Endocrinology
135:
2398-2403,
1994[Abstract].
24.
Plaisancie, P,
Dumoulin V,
Chayvialle JA,
and
Cuber JC.
Luminal peptide YY-releasing factors in the isolated vascularly perfused rat colon.
J Endocrinol
151:
421-429,
1996[Abstract].
25.
Read, NW,
MacFarlane A,
and
Kinsman RI.
Effect of infusion of nutrient solutions into the ileum on gastrointestinal transit and plasma levels of neurotensin and enteroglucagon.
Gastroenterology
86:
274-280,
1984[ISI][Medline].
26.
Sarr, MG,
Foley MK,
Winters RC,
Duenes JA,
and
DiMagno EP.
Role of extrinsic innervation in carbohydrate-induced ileal modulation of pancreatic secretion and upper gut function.
Pancreas
14:
166-173,
1997[ISI][Medline].
27.
Siegle, M,
Schmid H,
and
Ehrlein HJ.
Effects of ileal infusions of nutrients on motor patterns of canine small intestine.
Am J Physiol Gastrointest Liver Physiol
259:
G78-G85,
1990
28.
Spiller, RC,
Trotman IF,
Higgins BE,
Ghatei MA,
Grimble GK,
Lee YC,
Bloom SR,
Misiewicz JJ,
and
Silk DBA
The ileal brakeinhibition of jejunal motility after ileal fat perfusion in man.
Gut
25:
365-374,
1984[Abstract].
29.
Walls, EK,
Phillips RJ,
Wang FB,
Holst JC,
and
Powley TL.
Suppression of meal size by intestinal nutrients is eliminated by celiac vagal deafferentation.
Am J Physiol Regulatory Integrative Comp Physiol
269:
R1410-R1419,
1995
30.
Welch, IM,
Cunningham KM,
and
Read NW.
Regulation of gastric emptying by ileal nutrients in humans.
Gastroenterology
94:
401-404,
1988[ISI][Medline].
31.
Wen, J,
Phillips SF,
Sarr MG,
Kost LJ,
and
Holst JJ.
PYY and GLP-1 contribute to feedback inhibition from the canine ileum and colon.
Am J Physiol Gastrointest Liver Physiol
269:
G945-G952,
1995